Long Term Debt Summary of RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc.'s latest annual long term debt in 2023 was 60 Thousand CAD , up 46.5% from previous year.
RepliCel Life Sciences Inc.'s latest quarterly long term debt in 2024 Q2 was 60.82 Thousand CAD , down 0.0% from previous quarter.
RepliCel Life Sciences Inc. reported annual long term debt of 40.95 Thousand CAD in 2022, up 19.56% from previous year.
RepliCel Life Sciences Inc. reported annual long term debt of 34.25 Thousand CAD in 2021, up 19.24% from previous year.
RepliCel Life Sciences Inc. reported quarterly long term debt of 60.82 Thousand CAD for 2024 Q2, down 0.0% from previous quarter.
RepliCel Life Sciences Inc. reported quarterly long term debt of 60 Thousand CAD for 2023 FY, up 46.5% from previous quarter.

Annual Long Term Debt Chart of RepliCel Life Sciences Inc. (2023 - 2002)

Historical Annual Long Term Debt of RepliCel Life Sciences Inc. (2023 - 2002)

Year	Long Term Debt	Long Term Debt Growth
2023	60 Thousand CAD	46.5%
2022	40.95 Thousand CAD	19.56%
2021	34.25 Thousand CAD	19.24%
2020	28.72 Thousand CAD	0.0%
2019	- CAD	0.0%
2018	- CAD	0.0%
2017	- CAD	0.0%
2016	- CAD	0.0%
2015	- CAD	0.0%
2014	- CAD	0.0%
2013	- CAD	0.0%
2012	- CAD	0.0%
2011	- CAD	0.0%
2010	- CAD	0.0%
2009	- CAD	0.0%
2008	- CAD	0.0%
2007	- CAD	0.0%
2006	- CAD	-100.0%
2005	3.13 Million CAD	6.86%
2004	2.92 Million CAD	0.0%
2003	- CAD	0.0%
2002	- USD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	60.82 Thousand CAD	1.37%
2024 Q2	60.82 Thousand CAD	0.0%
2023 FY	60 Thousand CAD	46.5%
2023 Q4	60 Thousand CAD	46.5%
2023 Q3	40.95 Thousand CAD	0.0%
2023 Q2	40.95 Thousand CAD	0.0%
2023 Q1	40.95 Thousand CAD	0.0%
2022 FY	40.95 Thousand CAD	19.56%
2022 Q2	37.42 Thousand CAD	4.55%
2022 Q1	35.79 Thousand CAD	4.5%
2022 Q3	39.15 Thousand CAD	4.61%
2022 Q4	40.95 Thousand USD	4.61%
2021 FY	34.25 Thousand CAD	19.24%
2021 Q4	34.25 Thousand CAD	4.61%
2021 Q3	32.74 Thousand CAD	4.6%
2021 Q1	28.72 Thousand CAD	0.0%
2021 Q2	31.3 Thousand CAD	8.97%
2020 Q4	28.72 Thousand CAD	-28.18%
2020 Q2	40 Thousand CAD	0.0%
2020 Q3	40 Thousand CAD	0.0%
2020 FY	28.72 Thousand CAD	0.0%
2020 Q1	- CAD	0.0%
2019 Q3	- CAD	0.0%
2019 Q4	- CAD	0.0%
2019 FY	- CAD	0.0%
2019 Q2	- CAD	0.0%
2019 Q1	- CAD	0.0%
2018 FY	- CAD	0.0%
2018 Q1	- CAD	0.0%
2018 Q2	- CAD	0.0%
2018 Q3	- CAD	0.0%
2018 Q4	- CAD	0.0%
2017 Q3	- CAD	0.0%
2017 Q1	- CAD	0.0%
2017 FY	- CAD	0.0%
2017 Q4	- CAD	0.0%
2017 Q2	- CAD	0.0%
2016 Q2	- CAD	0.0%
2016 Q4	- CAD	0.0%
2016 Q3	- CAD	0.0%
2016 FY	- CAD	0.0%
2016 Q1	- CAD	0.0%
2015 Q2	- CAD	0.0%
2015 FY	- CAD	0.0%
2015 Q3	- CAD	0.0%
2015 Q4	- CAD	0.0%
2015 Q1	- CAD	0.0%
2014 Q2	- CAD	0.0%
2014 Q4	- CAD	0.0%
2014 Q1	- CAD	0.0%
2014 FY	- CAD	0.0%
2014 Q3	- CAD	0.0%
2013 Q2	- CAD	0.0%
2013 FY	- CAD	0.0%
2013 Q4	- CAD	0.0%
2013 Q3	- CAD	0.0%
2013 Q1	- CAD	0.0%
2012 Q2	- CAD	0.0%
2012 FY	- CAD	0.0%
2012 Q3	- CAD	0.0%
2012 Q4	- CAD	0.0%
2012 Q1	- CAD	0.0%
2011 Q3	- CAD	0.0%
2011 Q4	- CAD	0.0%
2011 Q2	- CAD	0.0%
2011 FY	- CAD	0.0%
2011 Q1	- CAD	0.0%
2010 Q2	- CAD	0.0%
2010 Q3	- CAD	0.0%
2010 Q4	- CAD	0.0%
2010 FY	- CAD	0.0%
2010 Q1	- CAD	0.0%
2009 Q1	- CAD	0.0%
2009 Q4	- CAD	0.0%
2009 Q3	- CAD	0.0%
2009 Q2	- CAD	0.0%
2009 FY	- CAD	0.0%
2008 Q2	- CAD	0.0%
2008 Q4	- CAD	0.0%
2008 Q3	- CAD	0.0%
2008 Q1	- CAD	0.0%
2008 FY	- CAD	0.0%
2007 Q3	- CAD	0.0%
2007 FY	- CAD	0.0%
2007 Q1	- CAD	0.0%
2007 Q2	- CAD	0.0%
2007 Q4	- CAD	0.0%
2006 Q4	- CAD	0.0%
2006 Q1	3.16 Million CAD	1.09%
2006 FY	- CAD	-100.0%
2006 Q2	- CAD	-100.0%
2006 Q3	- CAD	0.0%
2005 Q4	3.13 Million CAD	0.89%
2005 FY	3.13 Million CAD	6.86%
2005 Q1	2.95 Million CAD	1.0%
2005 Q2	3.05 Million CAD	3.38%
2005 Q3	3.1 Million CAD	1.45%
2004 Q3	- CAD	0.0%
2004 Q1	- CAD	0.0%
2004 Q2	- CAD	0.0%
2004 Q4	2.92 Million CAD	0.0%
2004 FY	2.92 Million CAD	0.0%
2003 FY	- CAD	0.0%
2003 Q2	- USD	0.0%
2002 FY	- USD	0.0%
2002 Q4	- USD	0.0%

Peer Long Term Debt Comparison of RepliCel Life Sciences Inc.

Name	Long Term Debt	Long Term Debt Difference
Eiger BioPharmaceuticals, Inc.	- USD	-Infinity%
Nanobac Pharmaceuticals, Incorporated	- USD	-Infinity%
SQZ Biotechnologies Company	20.9 Million USD	99.713%
Evofem Biosciences, Inc.	8000.00 USD	-650.0%
Santhera Pharmaceuticals Holding AG	1.75 Million USD	96.582%
Mesoblast Limited	100.29 Million USD	99.94%
Propanc Biopharma, Inc.	58.64 Thousand USD	-2.316%
Genus plc	228.2 Million USD	99.974%
VioQuest Pharmaceuticals, Inc.	- USD	-Infinity%
CNBX Pharmaceuticals Inc.	- USD	-Infinity%
Marizyme, Inc.	667.12 Thousand USD	91.006%
ContraFect Corporation	2.21 Million USD	97.285%
Nymox Pharmaceutical Corporation	- USD	-Infinity%
PsyBio Therapeutics Corp.	- USD	-Infinity%
Sienna Biopharmaceuticals, Inc.	- USD	-Infinity%
RegeneRx Biopharmaceuticals, Inc.	1.4 Million USD	95.723%
Intellipharmaceutics International Inc.	- USD	-Infinity%
AXIM Biotechnologies, Inc.	5.42 Million USD	98.894%
MultiCell Technologies, Inc.	36.43 USD	-164599.424%
Accustem Sciences Inc.	- USD	-Infinity%
RVL Pharmaceuticals plc	55.61 Million USD	99.892%
EV Biologics, Inc.	- USD	-Infinity%
Q BioMed Inc.	- USD	-Infinity%
Emmaus Life Sciences, Inc.	2.22 Million USD	97.305%
Neon Bloom, Inc.	- USD	-Infinity%
Mosaic ImmunoEngineering Inc.	1.22 Million USD	95.115%
Biomind Labs Inc.	- USD	-Infinity%
TetraLogic Pharmaceuticals Corporation	- USD	-Infinity%
Pharming Group N.V.	166.1 Million USD	99.964%
Oncotelic Therapeutics, Inc.	1.89 Million USD	96.84%
Skye Bioscience, Inc.	171.23 Thousand USD	64.959%
Therapeutic Solutions International, Inc.	5512.00 USD	-988.534%
THC Farmaceuticals, Inc.	- USD	-Infinity%
Arch Therapeutics, Inc.	- USD	-Infinity%
IMV Inc.	27.39 Million USD	99.781%
Acro Biomedical Co., Ltd.	- USD	-Infinity%
Curative Biotechnology, Inc.	- USD	-Infinity%
GB Sciences, Inc.	322 Thousand USD	81.366%
Alpha Cognition Inc.	- USD	-Infinity%
HST Global, Inc.	- USD	-Infinity%
CSL Limited	11.23 Billion USD	99.999%
Halberd Corporation	150 Thousand USD	60.0%
Enzolytics Inc.	- USD	-Infinity%
Resverlogix Corp.	- USD	-Infinity%
Affymax, Inc.	- USD	-Infinity%
SYBLEU INC	300 Thousand USD	80.0%
Nuo Therapeutics, Inc.	164.2 Thousand USD	63.46%
argenx SE	15.35 Million USD	99.609%
MetaStat, Inc.	- USD	-Infinity%
Northwest Biotherapeutics, Inc.	20.31 Million USD	99.705%
Enzon Pharmaceuticals, Inc.	- USD	-Infinity%
Arno Therapeutics, Inc.	- USD	-Infinity%
RespireRx Pharmaceuticals Inc.	- USD	-Infinity%
GeneThera, Inc.	- USD	-Infinity%
Inhibitor Therapeutics, Inc.	- USD	-Infinity%
AVAX Technologies, Inc.	- USD	-Infinity%
Zenith Capital Corp.	4456.00 USD	-1246.499%
Genscript Biotech Corporation	287.12 Million USD	99.979%
Ember Therapeutics, Inc.	- USD	-Infinity%
Anthera Pharmaceuticals, Inc.	- USD	-Infinity%
Sigyn Therapeutics, Inc.	126.3 Thousand USD	52.495%
WPD Pharmaceuticals Inc.	229.29 Thousand USD	73.832%
American Oriental Bioengineering, Inc.	554.59 Thousand USD	89.181%
Provectus Biopharmaceuticals, Inc.	25.29 Thousand USD	-137.164%
Adynxx, Inc.	- USD	-Infinity%
Helix BioMedix, Inc.	- USD	-Infinity%
GlobeStar Therapeutics Corporation	- USD	-Infinity%
VitaSpring Biomedical Co. Ltd.	- USD	-Infinity%
Capstone Therapeutics Corp.	8.26 Million USD	99.274%
Cotinga Pharmaceuticals Inc.	- USD	-Infinity%
BioStem Technologies, Inc.	265.63 Thousand USD	77.413%
ONE Bio Corp.	592.19 Thousand USD	89.868%
Reve Technologies, Inc.	1064.00 USD	-5539.098%
Burzynski Research Institute, Inc.	- USD	-Infinity%
Wesana Health Holdings Inc.	- USD	-Infinity%
Agentix Corp.	- USD	-Infinity%
LadRx Corporation	- USD	-Infinity%
Cell Source, Inc.	- USD	-Infinity%
ProtoKinetix, Incorporated	- USD	-Infinity%
Regen BioPharma, Inc.	149.61 Thousand USD	59.897%
Regen BioPharma, Inc.	149.61 Thousand USD	59.897%
NovAccess Global Inc.	- USD	-Infinity%
Endonovo Therapeutics, Inc.	- USD	-Infinity%
Itoco Inc.	- USD	-Infinity%
Rasna Therapeutics, Inc.	- USD	-Infinity%
Pathfinder Cell Therapy, Inc.	- USD	-Infinity%
Kadimastem Ltd	229.69 Thousand USD	73.878%
Oncology Pharma Inc.	- USD	-Infinity%
Institute of Biomedical Research Corp.	- USD	-Infinity%
CytoDyn Inc.	141 Thousand USD	57.447%
Claritas Pharmaceuticals, Inc.	- USD	-Infinity%
NDT Pharmaceuticals Inc.	- USD	-Infinity%
Mobile Lads Corp.	- USD	-Infinity%
NanoSphere Health Sciences Inc.	- USD	-Infinity%
Qrons Inc.	80 Thousand USD	25.0%
Alseres Pharmaceuticals, Inc.	7.81 Million USD	99.233%
Advanced Proteome Therapeutics Corporation	- USD	-Infinity%
Nascent Biotech, Inc.	- USD	-Infinity%
Rebus Holdings, Inc.	- USD	-Infinity%
ImmunoCellular Therapeutics, Ltd.	369.04 Thousand USD	83.742%
International Stem Cell Corporation	445 Thousand USD	86.517%
Bioxytran, Inc.	- USD	-Infinity%
GlobeImmune, Inc.	- USD	-Infinity%
Predictive Technology Group, Inc.	- USD	-Infinity%
ProText Mobility, Inc.	- USD	-Infinity%
Cardax, Inc.	- USD	-Infinity%
VG Life Sciences Inc.	- USD	-Infinity%
Kaleido Biosciences, Inc.	- USD	-Infinity%
Advaxis, Inc.	8.15 Million USD	99.264%
Adhera Therapeutics, Inc.	- USD	-Infinity%
RenovaCare, Inc.	- USD	-Infinity%
Regnum Corp.	- USD	-Infinity%
Innovation Pharmaceuticals Inc.	457 Thousand USD	86.871%
Neutra Corp.	- USD	-Infinity%
Windtree Therapeutics, Inc.	1.16 Million USD	94.832%
PureTech Health plc	18.25 Million USD	99.671%
Coeptis Therapeutics, Inc.	150 Thousand USD	60.0%
IXICO plc	275 Thousand USD	78.182%
IntelGenx Technologies Corp.	11.83 Million USD	99.493%
Gelesis Holdings, Inc.	26.3 Million USD	99.772%
CSL Limited	11.23 Billion USD	99.999%
Cellectis S.A.	36.21 Million USD	99.834%

Global Stocks Search

RepliCel Life Sciences Inc. (REPCF)

Long Term Debt Summary of RepliCel Life Sciences Inc.

Annual Long Term Debt Chart of RepliCel Life Sciences Inc. (2023 - 2002)

Historical Annual Long Term Debt of RepliCel Life Sciences Inc. (2023 - 2002)

Peer Long Term Debt Comparison of RepliCel Life Sciences Inc.